UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' INVESTMENT - USD ($)	3 Months Ended			6 Months Ended
	Jun. 30, 2025		Jun. 30, 2024	Jun. 30, 2025		Jun. 30, 2024
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period	$ 2,479,417,503		$ 2,376,363,789	$ 2,472,099,655	[1]	$ 2,312,517,069
Issuance of common stock from stock plan transactions (in shares)				1,100,000
Issuance of common stock from stock plan transactions	1,416,982		3,408,322	$ 6,350,684		20,242,309
Repurchases of common stock (in shares)				(8,800,000)
Repurchases of common stock	(126,162,931)		(48,299,574)	$ (202,167,048)		(91,338,662)
Stock-based compensation expense related to stock options, employee stock purchases and restricted stock	7,488,526		10,922,998	16,160,289		21,396,790
Dividends declared	(26,342,490)		(27,627,119)	(53,321,754)		(55,370,601)
Capital contributions, net				442,500
Fair value of non-controlling interest in EyeLock LLC	656,000			656,000
Purchase of additional interest in BioCenturion LLC	(3,452,528)			(3,452,528)
Net income (loss)	95,983,189	[2]	86,040,438	190,857,234	[3]	194,271,153
Other comprehensive income (loss)	1,633,473		(509,327)	3,012,692		(1,418,531)
Balance at end of period	2,430,637,724		2,400,299,527	2,430,637,724		2,400,299,527
Parent
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period	2,474,826,003		2,376,363,789	2,467,950,655		2,312,517,069
Issuance of common stock from stock plan transactions	1,416,982		3,408,322	6,350,684		20,242,309
Repurchases of common stock	(126,162,931)		(48,299,574)	(202,167,048)		(91,338,662)
Stock-based compensation expense related to stock options, employee stock purchases and restricted stock	7,488,526		10,922,998	16,160,289		21,396,790
Dividends declared	(26,342,490)		(27,627,119)	(53,321,754)		(55,370,601)
Purchase of additional interest in BioCenturion LLC	1,139,021			1,139,021
Net income (loss)	96,039,584	[2]	86,040,438	190,913,629	[3]	194,271,153
Other comprehensive income (loss)	1,633,473		(509,327)	3,012,692		(1,418,531)
Balance at end of period	$ 2,430,038,168		$ 2,400,299,527	$ 2,430,038,168		$ 2,400,299,527
Common Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period (in shares)	224,817,117		231,198,885	227,207,472		231,455,443
Balance at beginning of period	$ 13,489,027		$ 13,871,933	$ 13,632,448		$ 13,887,326
Issuance of common stock from stock plan transactions (in shares)	405,697		433,321	1,115,693		1,377,666
Issuance of common stock from stock plan transactions	$ 24,342		$ 25,999	$ 66,942		$ 82,660
Repurchases of common stock (in shares)	(5,702,064)		(1,402,667)	(8,802,415)		(2,603,570)
Repurchases of common stock	$ (342,124)		$ (84,160)	$ (528,145)		$ (156,214)
Balance at end of period (in shares)	219,520,750		230,229,539	219,520,750		230,229,539
Balance at end of period	$ 13,171,245		$ 13,813,772	$ 13,171,245		$ 13,813,772
Additional  Paid-In Capital
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period	1,011,756,899		991,053,652	1,010,440,420		968,245,875
Issuance of common stock from stock plan transactions	1,392,640		3,382,323	6,283,742		20,159,649
Repurchases of common stock	(22,865,277)		(5,344,160)	(35,111,663)		(9,787,501)
Stock-based compensation expense related to stock options, employee stock purchases and restricted stock	7,488,526		10,922,998	16,160,289		21,396,790
Purchase of additional interest in BioCenturion LLC	1,139,021			1,139,021
Balance at end of period	998,911,809		1,000,014,813	998,911,809		1,000,014,813
Retained  Earnings
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period	1,454,610,199		1,378,904,530	1,450,287,128		1,336,940,990
Repurchases of common stock	(102,955,530)		(42,871,254)	(166,527,240)		(81,394,947)
Dividends declared	(26,342,490)		(27,627,119)	(53,321,754)		(55,370,601)
Net income (loss)	96,039,584	[2]	86,040,438	190,913,629	[3]	194,271,153
Balance at end of period	1,421,351,763		1,394,446,595	1,421,351,763		1,394,446,595
Accumulated  Other Comprehensive Income (Loss)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period	(5,030,122)		(7,466,326)	(6,409,341)		(6,557,122)
Other comprehensive income (loss)	1,633,473		(509,327)	3,012,692		(1,418,531)
Balance at end of period	(3,396,649)		(7,975,653)	(3,396,649)		(7,975,653)
Equity Attributable to Noncontrolling Interests
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period	4,591,500		0	4,149,000		0
Capital contributions, net				442,500
Fair value of non-controlling interest in EyeLock LLC	656,000			656,000
Purchase of additional interest in BioCenturion LLC	(4,591,549)			(4,591,549)
Net income (loss)	(56,395)	[2]		(56,395)	[3]
Balance at end of period	$ 599,556		$ 0	$ 599,556		$ 0

[1] The condensed consolidated balance sheet at December 31, 2024 has been derived from the audited consolidated financial statements at that date, but does not include all of the inflation and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

[2] Net income (loss) excludes net loss attributable to redeemable non-controlling interest of $332,739 for the three months ended June 30, 2025 (see Note 16).

[3] Net income (loss) excludes net loss attributable to redeemable non-controlling interest of $332,739 for the six months ended June 30, 2025 (see Note 16).